HomeAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
Previous close
$1.98
Year range
$1.96 - $31.28
Market cap
134.21M USD
Avg Volume
5.30M
P/E ratio
2.81
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 108.45M | 395.54% |
Operating expense | -23.94M | 7.17% |
Net income | 4.73M | 111.08% |
Net profit margin | 4.36 | 102.23% |
Earnings per share | 0.07 | 110.77% |
EBITDA | 2.24M | 105.03% |
Effective tax rate | 26.95% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 371.36M | 7.04% |
Total assets | 517.45M | 32.19% |
Total liabilities | 84.02M | 65.25% |
Total equity | 433.43M | — |
Shares outstanding | 67.78M | — |
Price to book | 0.30 | — |
Return on assets | 0.98% | — |
Return on capital | 1.12% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 4.73M | 111.08% |
Cash from operations | 13.55M | 127.27% |
Cash from investing | 20.92M | 109.17% |
Cash from financing | 230.00K | -99.90% |
Net change in cash | 34.94M | 177.29% |
Free cash flow | 32.82M | 196.84% |
About
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. Wikipedia
Founded
2013
Website
Employees
384
